Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,578.44
(
-0.04%
)
US TECH 100
23,468.80
(
-0.22%
)
Dow Jones
46,267.45
(
0.13%
)
Brent Oil
100.35
(
3.67%
)
Bitcoin
69,884.00
(
-1.43%
)
News Focus
News Focus
Post# of 257275
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122807
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: dewophile post# 205316

Thursday, 01/19/2017 7:22:30 PM

Thursday, January 19, 2017 7:22:30 PM

Post# of 257275
BMY won't pursue FDA accelerated approval for Opdivo/Yervoy combination in first-line NSCLC:

http://finance.yahoo.com/news/bristol-myers-squibb-provides-regulatory-233000138.html

No further information is being disclosed to maintain the integrity of ongoing Opdivo/Yervoy phase-3 trials in this setting.

BMY is -6% in AH trading on this news.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today